Invivyd posts CANOPY older-adult subgroup analysis presentation on pemivibart for COVID-19 prevention

Invivyd

Invivyd

IVVD

0.00
  • Invivyd published a CANOPY Phase 3 subgroup analysis of pemivibart for COVID-19 pre-exposure prevention in adults aged 65+.
  • Older-adult enrollment totaled 95 in Cohort A (immunocompromised) plus 88 in Cohort B (non-immunocompromised; 61 pemivibart, 27 placebo).
  • No RT-PCR-confirmed symptomatic COVID-19 cases occurred in the Cohort A older-adult subgroup through Month 6.
  • Cohort B older-adult subgroup reported 3 symptomatic cases through Month 6; 1 on pemivibart, 2 on placebo; estimated sRRR 77.9%.
  • Older-adult safety through Month 6 showed TEAEs of 63.2% in Cohort A plus 37.5% in Cohort B; no anaphylaxis reported in either subgroup.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.